JenaValve
Company Snapshot
Company Overview
JenaValve Technology, established in 2006, develops transcatheter aortic valve replacement (TAVR) systems. It first-generation transapical system, consisting of the JenaValve valve with Cathlete Plus delivery system, was commercialized under CE Mark approval for aortic valve stenosis and for aortic valve regurgitation. The new JenaValve Pericardial TAVR System consists of the Everdur pericardial aortic valve (manufactured at JenaValve’s U.K. facility) and the transfemoral delivery system. The bioprosthesis comprises a self-expanding nitinol stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques. The Coronatix transfemoral delivery catheter is designed to deliver the bioprosthesis using a simple stepped approach with anatomic positioning over the native valve. The system is available in three sizes intended for aortic annulus diameters from 21 mm to 27 mm. A larger bioprosthesis size is in development.
JenaValve In News
Company's Business Segments
- Product : Trilogy THV System, Aortic Regurgitation Trial Investigating Surgery (ARTIST) Trial, Others
- Service : Clinical Development, Partnerships and Training, Integrity and Compliance, Others
Applications/End User Industries
- Healthcare
- Hospitals and Clinics
- Life Sciences
- Cardiac Surgery
- Cardiology